Skip to main content
Top
Published in: Clinical Rheumatology 1/2018

01-01-2018 | Review Article

Systemic lupus erythematosus patients with high disease activity are associated with accelerated incidence of osteonecrosis: a systematic review and meta-analysis

Authors: Kui Zhang, Yan Zheng, Junfeng Jia, Jin Ding, Zhenbiao Wu

Published in: Clinical Rheumatology | Issue 1/2018

Login to get access

Abstract

Osteonecrosis (ON) is one of the serious complications for systemic lupus erythematosus (SLE); we aimed to study the risk relationship between disease activity and incidence of ON in SLE patients. The PubMed, Embase, and Cochrane library databases were searched for papers published up to May 2016 with English-language restriction; studies that compared disease activity between SLE patients with and without ON would be included, and eight studies involving a total of 1119 SLE patients were included. The incidence of ON in SLE was significantly associated with high patient’s disease activity, including the degree (pool odds ratio 2.54, 95% confidence interval [CI] [1.33, 4.86], p = 0.005) and the scores (mean difference 2.33, 95% CI [0.86, 3.80], p = 0.002). Besides, immunosuppressive drug use was also a significant risk factor for ON (p = 0.00001), while antimalarial treatment played a protective role (p = 0.01). No evidence of publication bias was detected. In conclusion, disease activity is a significant and independent risk factor for ON, and higher disease activity score is associated with accelerated incidence of ON in SLE patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Oinuma K, Harada Y, Nawata Y, Takabayashi K, Abe I, Kamikawa K, Moriya H (2001) Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 60(12):1145–1148CrossRefPubMedPubMedCentral Oinuma K, Harada Y, Nawata Y, Takabayashi K, Abe I, Kamikawa K, Moriya H (2001) Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 60(12):1145–1148CrossRefPubMedPubMedCentral
2.
go back to reference Abeles M, Urman JD, Rothfield NF (1978) Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy. Arch Intern Med 138(5):750–754CrossRefPubMed Abeles M, Urman JD, Rothfield NF (1978) Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy. Arch Intern Med 138(5):750–754CrossRefPubMed
3.
go back to reference Koo KH, Kim R (1995) Quantifying the extent of osteonecrosis of the femoral head. A new method using MRI. J Bone Joint Surg Br 77(6):875–880PubMed Koo KH, Kim R (1995) Quantifying the extent of osteonecrosis of the femoral head. A new method using MRI. J Bone Joint Surg Br 77(6):875–880PubMed
4.
go back to reference Mont MA, Carbone JJ, Fairbank AC (1996) Core decompression versus nonoperative management for osteonecrosis of the hip. Clin Orthop Relat Res 324:169–178CrossRef Mont MA, Carbone JJ, Fairbank AC (1996) Core decompression versus nonoperative management for osteonecrosis of the hip. Clin Orthop Relat Res 324:169–178CrossRef
5.
go back to reference Mont MA, Jones LC, Hungerford DS (2006) Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am 88(5):1117–1132PubMed Mont MA, Jones LC, Hungerford DS (2006) Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am 88(5):1117–1132PubMed
6.
go back to reference Weiner ES, Abeles M (1989) Aseptic necrosis and glucocorticosteroids in systemic lupus erythematosus: a reevaluation. J Rheumatol 16(5):604–608PubMed Weiner ES, Abeles M (1989) Aseptic necrosis and glucocorticosteroids in systemic lupus erythematosus: a reevaluation. J Rheumatol 16(5):604–608PubMed
7.
go back to reference Nilsen KH (1977) Systemic lupus erythematosus and avascular bone necrosis. N Z Med J 85(589):472–475PubMed Nilsen KH (1977) Systemic lupus erythematosus and avascular bone necrosis. N Z Med J 85(589):472–475PubMed
8.
go back to reference Hungerford DS, Zizic TM II (1980) The treatment of ischemic necrosis of bone in systemic lupus erythematosus. Medicine 59(2):143–148CrossRefPubMed Hungerford DS, Zizic TM II (1980) The treatment of ischemic necrosis of bone in systemic lupus erythematosus. Medicine 59(2):143–148CrossRefPubMed
9.
go back to reference Ehmke TA, Cherian JJ, Wu ES, Jauregui JJ, Banerjee S, Mont MA (2014) Treatment of osteonecrosis in systemic lupus erythematosus: a review. Curr Rheumatol Rep 16(9):441CrossRefPubMed Ehmke TA, Cherian JJ, Wu ES, Jauregui JJ, Banerjee S, Mont MA (2014) Treatment of osteonecrosis in systemic lupus erythematosus: a review. Curr Rheumatol Rep 16(9):441CrossRefPubMed
10.
go back to reference Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M (1997) Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 24(4):654–662PubMed Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M (1997) Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 24(4):654–662PubMed
11.
go back to reference Zhu KK, Xu WD, Pan HF, Zhang M, Ni J, Ge FY, Ye DQ (2014) The risk factors of avascular necrosis in patients with systemic lupus erythematosus: a meta-analysis. Inflammation 37(5):1852–1864CrossRefPubMed Zhu KK, Xu WD, Pan HF, Zhang M, Ni J, Ge FY, Ye DQ (2014) The risk factors of avascular necrosis in patients with systemic lupus erythematosus: a meta-analysis. Inflammation 37(5):1852–1864CrossRefPubMed
12.
go back to reference Ibanez D, Gladman DD, Urowitz MB (2005) Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 32(5):824–827PubMed Ibanez D, Gladman DD, Urowitz MB (2005) Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 32(5):824–827PubMed
13.
go back to reference Fialho SC, Bonfa E, Vitule LF, D’Amico E, Caparbo V, Gualandro S, Pereira RM (2007) Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus. Lupus 16(4):239–244CrossRefPubMed Fialho SC, Bonfa E, Vitule LF, D’Amico E, Caparbo V, Gualandro S, Pereira RM (2007) Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus. Lupus 16(4):239–244CrossRefPubMed
14.
go back to reference Uea-areewongsa P, Chaiamnuay S, Narongroeknawin P, Asavatanabodee P (2009) Factors associated with osteonecrosis in Thai lupus patients: a case control study. J Clin Rheumatol 15(7):345–349CrossRefPubMed Uea-areewongsa P, Chaiamnuay S, Narongroeknawin P, Asavatanabodee P (2009) Factors associated with osteonecrosis in Thai lupus patients: a case control study. J Clin Rheumatol 15(7):345–349CrossRefPubMed
15.
go back to reference Prasad R, Ibanez D, Gladman D, Urowitz M (2007) The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case-control study of inception patients. Lupus 16(3):157–162CrossRefPubMed Prasad R, Ibanez D, Gladman D, Urowitz M (2007) The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case-control study of inception patients. Lupus 16(3):157–162CrossRefPubMed
16.
go back to reference Pineau CA, Urowitz MB, Fortin PJ, Ibanez D, Gladman DD (2004) Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density. Lupus 13(6):436–441CrossRefPubMed Pineau CA, Urowitz MB, Fortin PJ, Ibanez D, Gladman DD (2004) Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density. Lupus 13(6):436–441CrossRefPubMed
17.
go back to reference Kuroda T, Tanabe N, Wakamatsu A, Takai C, Sato H, Nakatsue T, Wada Y, Nakano M, Narita I (2015) High triglyceride is a risk factor for silent osteonecrosis of the femoral head in systemic lupus erythematosus. Clin Rheumatol 34(12):2071–2077CrossRefPubMed Kuroda T, Tanabe N, Wakamatsu A, Takai C, Sato H, Nakatsue T, Wada Y, Nakano M, Narita I (2015) High triglyceride is a risk factor for silent osteonecrosis of the femoral head in systemic lupus erythematosus. Clin Rheumatol 34(12):2071–2077CrossRefPubMed
18.
go back to reference Yang Y, Kumar S, Lim LS, Silverman ED, Levy DM (2015) Risk factors for symptomatic avascular necrosis in childhood-onset systemic lupus erythematosus. J Rheumatol 42(12):2304–2309CrossRefPubMed Yang Y, Kumar S, Lim LS, Silverman ED, Levy DM (2015) Risk factors for symptomatic avascular necrosis in childhood-onset systemic lupus erythematosus. J Rheumatol 42(12):2304–2309CrossRefPubMed
19.
go back to reference Sekiya F, Yamaji K, Yang K, Tsuda H, Takasaki Y (2010) Investigation of occurrence of osteonecrosis of the femoral head after increasing corticosteroids in patients with recurring systemic lupus erythematosus. Rheumatol Int 30(12):1587–1593CrossRefPubMed Sekiya F, Yamaji K, Yang K, Tsuda H, Takasaki Y (2010) Investigation of occurrence of osteonecrosis of the femoral head after increasing corticosteroids in patients with recurring systemic lupus erythematosus. Rheumatol Int 30(12):1587–1593CrossRefPubMed
20.
go back to reference Mont MA, Pivec R, Banerjee S, Issa K, Elmallah RK, Jones LC (2015) High-dose corticosteroid use and risk of hip osteonecrosis: meta-analysis and systematic literature review. J Arthroplast 30(9):1506–1512.e5CrossRef Mont MA, Pivec R, Banerjee S, Issa K, Elmallah RK, Jones LC (2015) High-dose corticosteroid use and risk of hip osteonecrosis: meta-analysis and systematic literature review. J Arthroplast 30(9):1506–1512.e5CrossRef
21.
22.
go back to reference Sayarlioglu M, Yuzbasioglu N, Inanc M, Kamali S, Cefle A, Karaman O, Onat AM, Avan R, Cetin GY, Gul A, Ocal L, Aral O (2012) Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatol Int 32(1):177–182CrossRefPubMed Sayarlioglu M, Yuzbasioglu N, Inanc M, Kamali S, Cefle A, Karaman O, Onat AM, Avan R, Cetin GY, Gul A, Ocal L, Aral O (2012) Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatol Int 32(1):177–182CrossRefPubMed
23.
go back to reference Mok MY, Farewell VT, Isenberg DA (2000) Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies? Ann Rheum Dis 59(6):462–467CrossRefPubMedPubMedCentral Mok MY, Farewell VT, Isenberg DA (2000) Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies? Ann Rheum Dis 59(6):462–467CrossRefPubMedPubMedCentral
24.
go back to reference Dubois EL, Cozen L (1960) Avascular (aseptic) bone necrosis associated with systemic lupus erythematosus. JAMA 174:966–971CrossRefPubMed Dubois EL, Cozen L (1960) Avascular (aseptic) bone necrosis associated with systemic lupus erythematosus. JAMA 174:966–971CrossRefPubMed
25.
go back to reference Becker A, Fischer R, Scherbaum WA, Schneider M (2001) Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage. Lupus 10(11):809–814CrossRefPubMed Becker A, Fischer R, Scherbaum WA, Schneider M (2001) Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage. Lupus 10(11):809–814CrossRefPubMed
26.
go back to reference Zonana-Nacach A, Barr SG, Magder LS, Petri M, Farnell J, Rosenburg R, Veale DJ, Breedveld FC, Emery P, Tak PP (1801–1808) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43(8):2000 Zonana-Nacach A, Barr SG, Magder LS, Petri M, Farnell J, Rosenburg R, Veale DJ, Breedveld FC, Emery P, Tak PP (1801–1808) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43(8):2000
27.
go back to reference Jardinet D, Lefebvre C, Depresseux G, Lambert M, Devogelaer JP, Houssiau FA (2000) Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology (Oxford) 39(4):389–392CrossRef Jardinet D, Lefebvre C, Depresseux G, Lambert M, Devogelaer JP, Houssiau FA (2000) Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology (Oxford) 39(4):389–392CrossRef
28.
go back to reference Mok CC, Lau CS, Wong RW (1998) Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 37(8):895–900CrossRefPubMed Mok CC, Lau CS, Wong RW (1998) Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 37(8):895–900CrossRefPubMed
29.
go back to reference Rascu A, Manger K, Kraetsch HG, Kalden JR, Manger B (1996) Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation? Lupus 5(4):323–327CrossRefPubMed Rascu A, Manger K, Kraetsch HG, Kalden JR, Manger B (1996) Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation? Lupus 5(4):323–327CrossRefPubMed
30.
go back to reference Klipper AR, Stevens MB, Zizic TM, Hungerford DS (1976) Ischemic necrosis of bone in systemic lupus erythematosus. Medicine (Baltimore) 55(3):251–257CrossRef Klipper AR, Stevens MB, Zizic TM, Hungerford DS (1976) Ischemic necrosis of bone in systemic lupus erythematosus. Medicine (Baltimore) 55(3):251–257CrossRef
32.
go back to reference Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, Hallet DC, Cook RJ (2001) Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol 28(4):761–765PubMed Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, Hallet DC, Cook RJ (2001) Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol 28(4):761–765PubMed
33.
go back to reference Zhao L, Wu X, Wu H, Su J, Zhang W, Zhao Y, Zhang X, Zheng W (2016) Symptomatic knee osteonecrosis in patients with systemic lupus erythematosus: a case-control study. Rheumatol Int 36(8):1105–1111CrossRefPubMed Zhao L, Wu X, Wu H, Su J, Zhang W, Zhao Y, Zhang X, Zheng W (2016) Symptomatic knee osteonecrosis in patients with systemic lupus erythematosus: a case-control study. Rheumatol Int 36(8):1105–1111CrossRefPubMed
Metadata
Title
Systemic lupus erythematosus patients with high disease activity are associated with accelerated incidence of osteonecrosis: a systematic review and meta-analysis
Authors
Kui Zhang
Yan Zheng
Junfeng Jia
Jin Ding
Zhenbiao Wu
Publication date
01-01-2018
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 1/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-017-3820-5

Other articles of this Issue 1/2018

Clinical Rheumatology 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.